Pharsight

Imvexxy generic

Imvexxy is an estradiol-based drug owned by Therapeuticsmd Inc. It was first authorized for market use on May 29, 2018.

When will Imvexxy generic be available?

The generic release of Imvexxy is anticipated to be possible after February 2, 2034. This follows the expiration of the drug's last patent.

Imvexxy uses

Imvexxy is used for the treatment of a variety of symptoms of vulvar and vaginal atrophy, including dyspareunia. The drug's active ingredient, estradiol, contributes to its efficacy.

Imvexxy patent expiration

Imvexxy holds a total of 20 drug patents, none of which have expired as of now. The last patent for the Imvexxy generic is due to expire on February 2, 2034. Below are the details of the patent:

EPO Oppostions filed on Imvexxy

Imvexxy dosage

Want to ask something?